Working... Menu
Trial record 93 of 179 for:    Phospholipids

A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002275
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : February 20, 2009
Information provided by:

Brief Summary:

The objectives of this study are:

To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP). To compare the effects of the two lipid emulsions on immunologic function in AIDS patients. To compare the effect of the two lipid emulsions on HIV load in AIDS patients as measured by reverse transcriptase (RT) in culture. To determine whether a decrease in HIV infectivity is greater in patients given a parenteral feeding regimen containing Liposyn II 20 percent or Liposyn III 2 percent.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Fat Emulsion 2% Drug: Fat Emulsion 20% Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Lipid-Based Parenteral Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome and Pneumocystis Carinii Pneumonia. A Comparison of Two Lipid Formulations

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS Pneumonia

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Concurrent Medication:


  • All drugs used for the standard treatment of Pneumocystis carinii pneumonia (PCP).
  • Other drugs for treatment of other AIDS conditions if they have been started more than 3 months prior to study entry.

Patients must have:

  • Diagnosis of AIDS.
  • Weight loss > 10 percent of premorbid body weight.
  • First or second episode of acute Pneumocystis carinii pneumonia (PCP).

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Do Not Resuscitate (DNR) status.
  • Biliary stasis.

Patients with the following are excluded:

  • Do Not Resuscitate (DNR) status.
  • Biliary stasis.

Prior Medication:

Excluded within 3 months of study entry:

  • Immunomodulators.
  • Antiviral new DT

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00002275

Layout table for location information
United States, New Jersey
East Orange Veterans Administration Med Ctr
East Orange, New Jersey, United States, 07018
Sponsors and Collaborators

Layout table for additonal information Identifier: NCT00002275     History of Changes
Other Study ID Numbers: 041B
First Posted: August 31, 2001    Key Record Dates
Last Update Posted: February 20, 2009
Last Verified: February 2009

Keywords provided by Abbott:
Weight Loss
Pneumonia, Pneumocystis carinii
Parenteral Nutrition
Acquired Immunodeficiency Syndrome

Additional relevant MeSH terms:
Layout table for MeSH terms
Soybean oil, phospholipid emulsion
HIV Infections
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
Pneumonia, Pneumocystis
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immune System Diseases
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Slow Virus Diseases
Lung Diseases, Fungal
Pneumocystis Infections
Fat Emulsions, Intravenous
Parenteral Nutrition Solutions
Pharmaceutical Solutions